GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials.

We synthesize current evidence of GLP-1 RAs on risk of optic nerve or vision-threatening events from randomized controlled trials (RCTs) in patients with type 2 diabetes or cardiometabolic diseases.

我们综合了当前关于GLP-1 RAs对2型糖尿病或心代谢疾病患者视神经或视力威胁性事件风险的随机对照试验（RCTs）的证据。

data_source

A total of 83,288 participants with type 2 diabetes/cardiometabolic diseases from 20 published RCTs were analyzed following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).

对20项已发表的随机对照试验(RCTs)中的83,288名2型糖尿病/心血管代谢疾病患者进行了分析，遵循了系统评价和荟萃分析的首选报告项目(Preferred Reporting Items for Systematic reviews and Meta-Analyses, PRISMA)。

study_selection

RCTs investigating GLP-1 RAs for type 2 diabetes/cardiometabolic disease populations and reported optic nerve or vision-related adverse events were assessed.

评估了研究GLP-1 RAs对2型糖尿病/心血管代谢疾病人群的影响，并报告了视神经或与视力相关的不良事件的RCTs。

data_extraction

Primary outcome was a composite of optic nerve and/or vision-threatening serious adverse events, including ION, ocular ischemic syndrome, papilledema, blindness, blurred vision, visual impairment, and reduced visual acuity.

主要结果是视神经和/或视力威胁性严重不良事件的复合指标，包括视神经炎、眼部缺血综合征、视乳头水肿、失明、视力模糊、视力损害和视力减退。

Odds ratios (ORs) were derived.

通过计算获得了比值比（ORs）。

data_synthesis

Type 2 diabetes occurred in 76.4% of participants.

76.4%的参与者发生了2型糖尿病。

Over mean follow-up duration of 2.97 years (estimated cumulative exposure of 240,334 patient-years), GLP-1 RA use was not associated with increased risk of primary end point (OR 1.20, 95% CI 0.73-1.97, I2 = 0%).

在平均随访时间为2.97年（估计累积暴露量为240,334患者年）的情况下，GLP-1 RA的使用并未与主要终点风险增加相关（OR 1.20，95%置信区间0.73-1.97，I2 = 0%）。

Prespecified individual adverse events, including ION (OR 1.50, 95% CI 0.49-4.63), and vision loss/disturbance events (OR 1.08, 95% CI 0.60-1.94) were not significantly associated with GLP-1 RA use.

预先设定的个别不良事件，包括离子通道阻滞（OR 1.50, 95% CI 0.49-4.63）和视力丧失/干扰事件（OR 1.08, 95% CI 0.60-1.94），与GLP-1 RA的使用没有显著关联。

limitations

RCTs reported vision-threatening events as adverse events rather than as prespecified outcomes.

随机对照试验将视力威胁性事件报告为不良事件，而不是作为预先设定的结果。

Conclusions

Based on a large number of patients who contributed to a meta-analysisof RCTs involving participants with type 2 diabetes and cardiometabolic disease, GLP-1 RAs were not associated with an increased risk of optic nerve/vision-threatening events.

基于大量参与涉及2型糖尿病和心代谢疾病的随机对照试验荟萃分析的患者数据，GLP-1 RAs与增加视神经/视力威胁性事件的风险无关。